Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.

We have previously described the generation of a novel Ebola virus (EBOV) vaccine platform based on (a) replication-competent rabies virus (RABV), (b) replication-deficient RABV, or (c) chemically inactivated RABV expressing EBOV glycoprotein (GP). Mouse studies demonstrated safety, immunogenicity,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Joseph E Blaney, Andrea Marzi, Mallory Willet, Amy B Papaneri, Christoph Wirblich, Friederike Feldmann, Michael Holbrook, Peter Jahrling, Heinz Feldmann, Matthias J Schnell
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Immunologic diseases. Allergy RC581-607 Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/60fe6f225613448a9bacf31d5f5b2477
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:60fe6f225613448a9bacf31d5f5b2477
record_format	dspace
spelling	oai:doaj.org-article:60fe6f225613448a9bacf31d5f5b24772021-11-18T06:05:35ZAntibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.1553-73661553-737410.1371/journal.ppat.1003389https://doaj.org/article/60fe6f225613448a9bacf31d5f5b24772013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23737747/?tool=EBIhttps://doaj.org/toc/1553-7366https://doaj.org/toc/1553-7374We have previously described the generation of a novel Ebola virus (EBOV) vaccine platform based on (a) replication-competent rabies virus (RABV), (b) replication-deficient RABV, or (c) chemically inactivated RABV expressing EBOV glycoprotein (GP). Mouse studies demonstrated safety, immunogenicity, and protective efficacy of these live or inactivated RABV/EBOV vaccines. Here, we evaluated these vaccines in nonhuman primates. Our results indicate that all three vaccines do induce potent immune responses against both RABV and EBOV, while the protection of immunized animals against EBOV was largely dependent on the quality of humoral immune response against EBOV GP. We also determined if the induced antibodies against EBOV GP differ in their target, affinity, or the isotype. Our results show that IgG1-biased humoral responses as well as high levels of GP-specific antibodies were beneficial for the control of EBOV infection after immunization. These results further support the concept that a successful EBOV vaccine needs to induce strong antibodies against EBOV. We also showed that a dual vaccine against RABV and filoviruses is achievable; therefore addressing concerns for the marketability of this urgently needed vaccine.Joseph E BlaneyAndrea MarziMallory WilletAmy B PapaneriChristoph WirblichFriederike FeldmannMichael HolbrookPeter JahrlingHeinz FeldmannMatthias J SchnellPublic Library of Science (PLoS)articleImmunologic diseases. AllergyRC581-607Biology (General)QH301-705.5ENPLoS Pathogens, Vol 9, Iss 5, p e1003389 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Biology (General) QH301-705.5
spellingShingle	Immunologic diseases. Allergy RC581-607 Biology (General) QH301-705.5 Joseph E Blaney Andrea Marzi Mallory Willet Amy B Papaneri Christoph Wirblich Friederike Feldmann Michael Holbrook Peter Jahrling Heinz Feldmann Matthias J Schnell Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.
description	We have previously described the generation of a novel Ebola virus (EBOV) vaccine platform based on (a) replication-competent rabies virus (RABV), (b) replication-deficient RABV, or (c) chemically inactivated RABV expressing EBOV glycoprotein (GP). Mouse studies demonstrated safety, immunogenicity, and protective efficacy of these live or inactivated RABV/EBOV vaccines. Here, we evaluated these vaccines in nonhuman primates. Our results indicate that all three vaccines do induce potent immune responses against both RABV and EBOV, while the protection of immunized animals against EBOV was largely dependent on the quality of humoral immune response against EBOV GP. We also determined if the induced antibodies against EBOV GP differ in their target, affinity, or the isotype. Our results show that IgG1-biased humoral responses as well as high levels of GP-specific antibodies were beneficial for the control of EBOV infection after immunization. These results further support the concept that a successful EBOV vaccine needs to induce strong antibodies against EBOV. We also showed that a dual vaccine against RABV and filoviruses is achievable; therefore addressing concerns for the marketability of this urgently needed vaccine.
format	article
author	Joseph E Blaney Andrea Marzi Mallory Willet Amy B Papaneri Christoph Wirblich Friederike Feldmann Michael Holbrook Peter Jahrling Heinz Feldmann Matthias J Schnell
author_facet	Joseph E Blaney Andrea Marzi Mallory Willet Amy B Papaneri Christoph Wirblich Friederike Feldmann Michael Holbrook Peter Jahrling Heinz Feldmann Matthias J Schnell
author_sort	Joseph E Blaney
title	Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.
title_short	Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.
title_full	Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.
title_fullStr	Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.
title_full_unstemmed	Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.
title_sort	antibody quality and protection from lethal ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/60fe6f225613448a9bacf31d5f5b2477
work_keys_str_mv	AT josepheblaney antibodyqualityandprotectionfromlethalebolaviruschallengeinnonhumanprimatesimmunizedwithrabiesvirusbasedbivalentvaccine AT andreamarzi antibodyqualityandprotectionfromlethalebolaviruschallengeinnonhumanprimatesimmunizedwithrabiesvirusbasedbivalentvaccine AT mallorywillet antibodyqualityandprotectionfromlethalebolaviruschallengeinnonhumanprimatesimmunizedwithrabiesvirusbasedbivalentvaccine AT amybpapaneri antibodyqualityandprotectionfromlethalebolaviruschallengeinnonhumanprimatesimmunizedwithrabiesvirusbasedbivalentvaccine AT christophwirblich antibodyqualityandprotectionfromlethalebolaviruschallengeinnonhumanprimatesimmunizedwithrabiesvirusbasedbivalentvaccine AT friederikefeldmann antibodyqualityandprotectionfromlethalebolaviruschallengeinnonhumanprimatesimmunizedwithrabiesvirusbasedbivalentvaccine AT michaelholbrook antibodyqualityandprotectionfromlethalebolaviruschallengeinnonhumanprimatesimmunizedwithrabiesvirusbasedbivalentvaccine AT peterjahrling antibodyqualityandprotectionfromlethalebolaviruschallengeinnonhumanprimatesimmunizedwithrabiesvirusbasedbivalentvaccine AT heinzfeldmann antibodyqualityandprotectionfromlethalebolaviruschallengeinnonhumanprimatesimmunizedwithrabiesvirusbasedbivalentvaccine AT matthiasjschnell antibodyqualityandprotectionfromlethalebolaviruschallengeinnonhumanprimatesimmunizedwithrabiesvirusbasedbivalentvaccine
_version_	1718424605652156416

Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.

Ejemplares similares